Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K; DITTO-HCV Study Group. Lagging M, et al. Among authors: neumann au. PLoS One. 2011 Feb 24;6(2):e17232. doi: 10.1371/journal.pone.0017232. PLoS One. 2011. PMID: 21390311 Free PMC article. Clinical Trial.
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.
Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, Lurie Y, Gianfranco E, Vrolijk JM, Esteban JI, Hezode C, Lagging M, Negro F, Soulier A, Verheij-Hart E, Hansen B, Tal R, Ferrari C, Schalm SW, Neumann AU; DITTO-HCV Study Group. Zeuzem S, et al. Among authors: neumann au. J Hepatol. 2005 Aug;43(2):250-7. doi: 10.1016/j.jhep.2005.05.016. J Hepatol. 2005. PMID: 16082736 Clinical Trial.
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. Lagging M, et al. Among authors: neumann au. Hepatology. 2006 Dec;44(6):1617-25. doi: 10.1002/hep.21407. Hepatology. 2006. PMID: 17133471 Clinical Trial.
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups. Askarieh G, et al. Among authors: neumann au. Hepatology. 2010 May;51(5):1523-30. doi: 10.1002/hep.23509. Hepatology. 2010. PMID: 20186843 Clinical Trial.
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E, Negro F, Missale G, Neumann AU, Hellstrand K; DITTO-HCV Study Group. Westin J, et al. Among authors: neumann au. J Viral Hepat. 2007 Jan;14(1):29-35. doi: 10.1111/j.1365-2893.2006.00777.x. J Viral Hepat. 2007. PMID: 17212641 Clinical Trial.
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
Söderholm J, Waldenström J, Askarieh G, Pilli M, Bochud PY, Negro F, Pawlotsky JM, Zeuzem S, Ferrari C, Norkrans G, Wejstål R, Westin J, Neumann AU, Haagmans BL, Lindh M, Missale G, Hellstrand K, Lagging M. Söderholm J, et al. Among authors: neumann au. PLoS One. 2013;8(2):e56991. doi: 10.1371/journal.pone.0056991. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437290 Free PMC article.
132 results